STOCK TITAN

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
fda approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.98%
Tags
conferences
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

272.77M
103.90M
1.35%
78.05%
21.73%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp